Company intelligence / Profile preview
Mapi Pharma
Ness Ziona, Israelmapi-pharma.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
Mapi Pharma has completed pivotal Phase III trials for its lead product GA Depot—a once-monthly long acting glatiramer acetate injection for relapsing multiple sclerosis. The NDA was accepted by the FDA with a PDUFA date of March 2024. Clinical data show improved safety and tolerability compared to existing therapies. Other programs are in mid-stage development targeting neurological and metabolic diseases.
- Therapeutic areas
- PsychiatryNeurologyMetabolic Disorders
- Modalities
- Small molecules (complex APIs)Depot injectable formulations (long acting injectables)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Viatris – exclusive license to commercialize GA Depot for relapsing forms of multiple sclerosis in key markets.
Beyond the preview
Go deeper on Mapi Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mapi Pharma.